These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25858607)

  • 41. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
    [No Abstract]   [Full Text] [Related]  

  • 42. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.
    Cruciani M; Parisi SG
    PLoS One; 2019; 14(9):e0222229. PubMed ID: 31504060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Integrase inhibitor in HIV therapy. Does dolutegravir set new standards?].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():58-9. PubMed ID: 25026862
    [No Abstract]   [Full Text] [Related]  

  • 44. Dolutegravir for treatment of HIV: SPRING forwards?
    Waters LJ; Barber TJ
    Lancet; 2013 Mar; 381(9868):705-6. PubMed ID: 23306001
    [No Abstract]   [Full Text] [Related]  

  • 45. Dolutegravir for the treatment of HIV.
    Katlama C; Murphy R
    Expert Opin Investig Drugs; 2012 Apr; 21(4):523-30. PubMed ID: 22380682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():2-6. PubMed ID: 25542868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
    Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
    AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
    Cavalcanti Jde S; Ferreira JL; Guimarães PM; Vidal JE; Brigido LF
    J Antimicrob Chemother; 2015 Mar; 70(3):926-9. PubMed ID: 25386009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
    Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrase strand transfer inhibitors in the management of HIV-positive individuals.
    Mesplède T; Quashie PK; Zanichelli V; Wainberg MA
    Ann Med; 2014 May; 46(3):123-9. PubMed ID: 24579911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
    Hoffmann C; Welz T; Sabranski M; Kolb M; Wolf E; Stellbrink HJ; Wyen C
    HIV Med; 2017 Jan; 18(1):56-63. PubMed ID: 27860104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy.
    Wijting IE; Rokx C; Zillikens MC; Smits SA; de Vries-Sluijs TE; Schurink CA; Bax HI; van der Ende ME; van Gorp EC; Nouwen JL; Verbon A; Bierman WF; Rijnders BJ
    Int J STD AIDS; 2019 Oct; 30(11):1042-1048. PubMed ID: 31431155
    [No Abstract]   [Full Text] [Related]  

  • 54. Raltegravir phase III study data released.
    AIDS Patient Care STDS; 2008 Nov; 22(11):917. PubMed ID: 19043838
    [No Abstract]   [Full Text] [Related]  

  • 55. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
    Delory T; Papot E; Rioux C; Charpentier C; Auge-Courtoi C; Michard F; Peytavin G; Descamps D; Matheron S; Yazdanpanah Y
    J Med Virol; 2016 Jul; 88(7):1204-10. PubMed ID: 26636432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients.
    Kumarasamy N; Prabhu S; Chandrasekaran E; Poongulali S; Pradeep A; Chitra D; Balakrishnan R; Benson CA
    Clin Infect Dis; 2019 Mar; 68(6):1048-1051. PubMed ID: 30192925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
    Rolón MJ; Figueroa MI; Sued O; Cahn P
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis.
    Parant F; Miailhes P; Brunel F; Gagnieu MC
    Ther Drug Monit; 2019 Aug; 41(4):444-451. PubMed ID: 30817698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two drugs regimens for HIV.
    Waters L; Church H
    Curr Opin Infect Dis; 2020 Feb; 33(1):28-33. PubMed ID: 31834030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.